Tezacaftor
Tezacaftor 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Cystic Fibrosis。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
21 项
全球在招研究
2 项
已进入 III/IV 期
8 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- Vertex Pharmaceuticals Incorporated
- University of Aarhus
- University Hospital, Tours
- University Hospital, Lille
- Hospices Civils de Lyon
- University of British Columbia
- Oslo University Hospital
- George Solomon
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
丹麦、法国、加拿大、挪威、美国、德国、意大利、瑞典
正在招募患者的 Tezacaftor 研究
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy
不适用招募中丹麦NCT05818319Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial
不适用招募中法国NCT06457451Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
不适用招募中法国NCT07314229Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population
不适用招募中法国NCT07303621Trikafta Exercise Study in Cystic Fibrosis
不适用招募中加拿大NCT05279040Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF
不适用招募中加拿大NCT05200429Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis
不适用招募中挪威NCT06284577Personalized Theratyping Trial
早期 I 期招募中美国NCT03587961Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
不适用招募中美国NCT06683092Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
不适用招募中法国NCT05937815Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators
不适用招募中德国NCT04732910Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
I 期招募中美国NCT07283770Sinus Disease in Young Children With Cystic Fibrosis
不适用招募中美国NCT06191640Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
I 期招募中美国NCT07437105Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
不适用招募中意大利NCT07363304Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
不适用招募中美国NCT04509050CFTR Modulators in Pregnancy and Postpartum
不适用招募中瑞典NCT06302270Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
IV 期招募中意大利NCT07809867Ensuring Access to Optimal Therapy in CF: The ENACT Study
IV 期招募中美国NCT07148739Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
不适用招募中法国NCT06507956Pharmacokinetics of Antibiotics in Patients With Cystic Fibrosis Trated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)
不适用招募中法国NCT07629986
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。